Myeloproliferative Neoplasms (MPNs) Patient Registry
Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Apr 28, 2016
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Myeloproliferative Neoplasms (MPNs) Patient Registry is a clinical trial designed to gather important information about various blood disorders known as myeloproliferative neoplasms. These include conditions like primary myelofibrosis, polycythemia vera, and essential thrombocythemia, among others. By collecting data from patients at different stages of their illness, the registry aims to improve our understanding of these diseases and how they affect individuals over time.
If you or a family member have been diagnosed with one of the specified MPNs, you may be eligible to join this study. There are no specific age or gender restrictions, and there are no exclusions based on other health conditions, making it open to a wide range of participants. If you decide to participate, you can expect to provide information about your health and possibly undergo tests to help researchers learn more about your condition. This study is currently recruiting participants and offers a chance to contribute to a valuable resource that may help improve treatment and care for people with MPNs in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Diagnosis of one of the following myeloproliferative neoplasms (MPNs):
- • Atypical CML (aCML)
- • Chronic eosinophilic leukemia-not otherwise specified (CEL, NOS),
- • Chronic myelomonocytic leukemia (CMML)
- • Chronic neutrophilic leukemia (CNL),
- • Essential thrombocythemia (ET),
- • Juvenile myelomonocytic leukemia (JMML),
- • Mastocytosis, MPN unclassifiable
- • MPN/MDS unclassifiable,
- • Primary myelofibrosis (PMF),
- • Post-essential thrombocythemia myelofibrosis (post-ET MF),
- • Post-polycythemia vera MF (post-PV MF)
- • Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T)
- Exclusion Criteria:
- • None
About University Health Network, Toronto
University Health Network (UHN), based in Toronto, is a leading academic health sciences center dedicated to advancing patient care through innovative research and education. As a prominent sponsor of clinical trials, UHN integrates cutting-edge scientific discoveries with clinical practice, facilitating the development of new therapies and treatment modalities. With a commitment to improving health outcomes, UHN collaborates with a diverse network of researchers, healthcare professionals, and industry partners, fostering an environment that prioritizes patient safety and ethical standards in clinical research. Through its extensive resources and expertise, UHN plays a pivotal role in transforming healthcare and enhancing the quality of life for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Toronto, Ontario, Canada
Patients applied
Trial Officials
Vikas Gupta, MD
Principal Investigator
University Health Network, Toronto
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials